關于多發性硬化<\/u><\/b> <\/p> \n
多發性硬化是一種以中樞神經系統炎性脫髓鞘病變為主要特點的免疫介導性疾病，其病因尚不明確，可能與遺傳、環境、病毒感染等多種因素相關[1]<\/sup>。髓鞘損傷會干擾大腦與身體其他部位之間的通信[3]<\/sup>，最終導致神經退行性損害，這一過程目前尚不可逆[10]<\/sup>。<\/p> \n 復發型多發性硬化包括臨床孤立綜合征、復發-緩解型疾病和活動性繼發進展型疾病[11]<\/sup>。其中，復發-緩解型疾病是診斷時最常見的類型，80%-85%的患者初診時被診斷為復發-緩解型疾病，其表現為明顯的復發和緩解過程，每次發作后均基本恢復，不留或僅留下輕微后遺癥[1]<\/sup>。約10%-15%的患者被診斷為進展型疾病[11]<\/sup>。<\/p> \n 關于熱珀西亞<\/u><\/b>®<\/sup><\/u><\/b>（鹽酸奧扎莫德膠囊）<\/u><\/b><\/p> \n 熱珀西亞<\/i>是一種口服鞘氨醇1-磷酸（S1P）受體調節劑，可高親和力結合S1P受體1和5（S1P1<\/sub>和S1P5<\/sub>）[12]<\/sup>。熱珀西亞<\/i>可適度抑制淋巴細胞遷出，減少外周血中淋巴細胞數量[7]<\/sup>。熱珀西亞<\/i>對多發性硬化發揮治療作用的機制尚不完全明確，可能與減少淋巴細胞向中樞神經系統的遷移相關[7]<\/sup>。<\/p> \n 熱珀西亞<\/i>已在全球多個國家和地區批準用于治療成人復發型多發性硬化癥和中度至重度活動性潰瘍性結腸炎成人患者。<\/p> \n 注：熱珀西亞潰瘍性結腸炎適應癥尚未在中國獲批<\/i><\/p> \n [1]《多發性硬化診斷和治療中國專家共識（2018版）》，中國神經免疫學和神經病學雜志2018年11月第25卷第6期 Chin J Neuroimmunol & Neurol 2018，Vol.25，No.6，387:394 <\/p>"];
$("#dvExtra").html(content_array[0]);})();
<\/sup>[2] National Multiple Sclerosis Society. Definition of MS. www.nationalmssociety.org\/What-is-MS\/Definition-of-MS<\/a>. Accessed on March 25, 2020<\/span>.
<\/sup>[3] National Multiple Sclerosis Society. What is Myelin? www.nationalmssociety.org\/What-is-MS\/Definition-of-MS\/Myelin<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[4] Manca R, et al. J Neurol Sci. 2018;388:115-127.
<\/sup>[5] Sumowski JF, et al. Neurology. 2018;90:278-288
<\/sup>[6] Campbell J, et al. Postgrad Med J. 2017;93(1097):143-147.
<\/sup>[7] Deloire, et al. Multiple Sclerosis 2010;16:581–587. <\/sup>
[8] Comi, G, Kappos, L, Selmaj, KW, et at. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicenter, randomized, minimum 12-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016\/S1474-4422(19)30239-X.
<\/sup>[9] Cohen, JA, Comi, G, Selmaj, KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomized, 24-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016\/S1474-4422(19)30238-8.
<\/sup>[10] National Multiple Sclerosis Society. What Causes MS? www.nationalmssociety.org\/What-is-MS\/What-Causes-MS<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[11] National Multiple Sclerosis Society. Types of MS. www.nationalmssociety.org\/What-is-MS\/Types-of-MS<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[12] ZEPOSIA (ozanimod) capsules for oral use. Bristol Myers Squibb Pharmaceutical Corporation. Full prescribing information. 3\/2020.<\/sup><\/p> \n